GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » Cyclically Adjusted Book per Share

Maxigen Biotech (TPE:1783) Cyclically Adjusted Book per Share : NT$13.96 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Maxigen Biotech's adjusted book value per share for the three months ended in Mar. 2025 was NT$16.578. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$13.96 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Maxigen Biotech's average Cyclically Adjusted Book Growth Rate was 3.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 6.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Maxigen Biotech was 6.50% per year. The lowest was 6.50% per year. And the median was 6.50% per year.

As of today (2025-05-30), Maxigen Biotech's current stock price is NT$43.40. Maxigen Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was NT$13.96. Maxigen Biotech's Cyclically Adjusted PB Ratio of today is 3.11.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Maxigen Biotech was 5.95. The lowest was 2.42. And the median was 3.41.


Maxigen Biotech Cyclically Adjusted Book per Share Historical Data

The historical data trend for Maxigen Biotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxigen Biotech Cyclically Adjusted Book per Share Chart

Maxigen Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 11.37 12.58 13.28 13.72

Maxigen Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.54 13.63 13.68 13.72 13.96

Competitive Comparison of Maxigen Biotech's Cyclically Adjusted Book per Share

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's Cyclically Adjusted PB Ratio falls into.


;
;

Maxigen Biotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Maxigen Biotech's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=16.578/134.9266*134.9266
=16.578

Current CPI (Mar. 2025) = 134.9266.

Maxigen Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201506 10.484 100.684 14.050
201509 10.411 100.392 13.992
201512 10.141 99.792 13.711
201603 9.708 100.470 13.037
201606 9.543 101.688 12.662
201609 9.519 101.861 12.609
201612 9.549 101.863 12.649
201703 9.493 102.862 12.452
201706 9.791 103.349 12.783
201709 9.884 104.136 12.807
201712 9.924 104.011 12.874
201803 10.030 105.290 12.853
201806 10.188 106.317 12.930
201809 10.409 106.507 13.187
201812 10.507 105.998 13.375
201903 10.591 107.251 13.324
201906 10.273 108.070 12.826
201909 10.518 108.329 13.100
201912 10.611 108.420 13.205
202003 10.738 108.902 13.304
202006 10.320 108.767 12.802
202009 10.471 109.815 12.865
202012 10.722 109.897 13.164
202103 10.992 111.754 13.271
202106 11.259 114.631 13.252
202109 12.653 115.734 14.751
202112 12.838 117.630 14.726
202203 13.107 121.301 14.579
202206 13.527 125.017 14.599
202209 14.048 125.227 15.136
202212 14.569 125.222 15.698
202303 15.110 127.348 16.009
202306 14.801 128.729 15.514
202309 15.395 129.860 15.996
202312 15.305 129.419 15.956
202403 15.212 131.776 15.576
202406 14.939 132.554 15.206
202409 14.984 133.029 15.198
202412 15.423 133.157 15.628
202503 16.578 134.927 16.578

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Maxigen Biotech  (TPE:1783) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Maxigen Biotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=43.40/13.96
=3.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Maxigen Biotech was 5.95. The lowest was 2.42. And the median was 3.41.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Maxigen Biotech Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Maxigen Biotech's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Maxigen Biotech Business Description

Traded in Other Exchanges
N/A
Address
No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.

Maxigen Biotech Headlines

No Headlines